Neurovascular Transduction During Exercise in Chronic Kidney Disease

The major problem addressed in this study is to understand mechanisms underlying poor exercise capacity in patients with chronic kidney disease (CKD). Prior research has found that CKD patients have an exaggerated increase in blood pressure during certain forms of exercise that could contribute to exercise dysfunction as well as cardiovascular disease. This study will test the mechanisms underlying this exaggerated blood pressure response, as well as the potential benefits of simple measures such as exercise training on a stationary bicycle, and treatment with 6R-BH4, a drug that is currently FDA-approved for the treatment of phenylketonuria, but has been shown to have beneficial effects on vascular health in patients with kidney disease. This study will also examine the effects of exercise with histidine and beta-alanine supplementation. Histidine and beta-alanine are two over-the-counter supplements commonly used to enhance sports performance in athletes.

Prior to the intervention portion of this study, the researchers will measure how much the vein constricts in response to adrenaline in CKD patients versus controls. The study will also measure muscle pH, and muscle oxygenation during exercise in CKD patients and controls.

The intervention portion of the study will test whether aerobic exercise training with and without 6R-BH4, or with and without histidine and beta-alanine supplementation might help muscle pH and adrenaline levels, vascular reactivity, muscle oxygenation, and the exaggerated blood pressure response during exercise in CKD patients. Participants will be randomized using a 2x2 factorial design to exercise training (ET) with 6R-BH4, ET with placebo, stretching (control condition to exercise) with 6R-BH4, and stretching with placebo. Participants will undergo exercise training on a stationary bicycle, or stretching exercises, 3 times per week for 6-14 weeks (depending on availability of the participant).

Inclusion criteria

for Chronic Kidney Disease Patients:

• Stage III or IV Chronic Kidney Disease, defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc/minute as calculated by the modified Modification of Diet in Renal Disease (MDRD) Study equation or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
• Stable renal function, with no greater than a 30% reduction in eGFR over the prior 3 months
• Does not exercise regularly (defined as exercising less than 20 minutes twice per week)
• Willing and able to cooperate with the study protocol

Inclusion criteria

for Control Study Participants:

• Does not exercise regularly (defined as exercising less than 20 minutes twice per week)
• Willing and able to cooperate with the study protocol

Exclusion criteria

• severe CKD (eGFR<15 cc/minute)
• ongoing drug or alcohol abuse
• diabetic neuropathy
• any serious systemic disease that might influence survival
• severe anemia with hgb level <9 g/dL
• clinical evidence of congestive heart failure or ejection fraction below 35%
• symptomatic heart disease determined by prior electrocardiogram, stress test, and/or history
• treatment with central alpha agonists (clonidine)
• uncontrolled hypertension with BP greater than 170/100 mm Hg
• low blood pressure with BP less than 100/50
• pregnancy or plans to become pregnant
• current treatment with monoamine oxidase (MAO) inhibitors
• inability to exercise on a stationary bicycle